Back to Search
Start Over
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review.
- Source :
-
Journal of Immunology Research . 12/16/2015, p968212-968212. 1p. 2 Charts. - Publication Year :
- 2015
-
Abstract
- Hodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and relapsed HL, leading to long-lasting responses in approximately 50% of relapsed patients and a minority of refractory patients. Patients progressing after intensive treatments, such as auto-SCT, have a very poor outcome. Allogeneic SCT represents the only strategy with a curative potential for these patients; however, its role is controversial. Based on recent knowledge of HL pathology, biology, and immunology, antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints are currently explored. This review will discuss the clinical results regarding auto-SCT and allo-SCT as well as the current role of emerging new treatment strategies. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 23148861
- Database :
- Academic Search Index
- Journal :
- Journal of Immunology Research
- Publication Type :
- Academic Journal
- Accession number :
- 113599017
- Full Text :
- https://doi.org/10.1155/2015/968212